Core Insights - Boundless Bio has appointed Dr. Robert Doebele as Chief Medical Officer, bringing over 15 years of oncology drug development experience to the company [1][2][3] Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to address oncogene amplified cancers, which affect over 14% of cancer patients [4] - The company is advancing its lead candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [4] Leadership and Experience - Dr. Doebele co-founded Rain Oncology, where he directed the development of therapies targeting oncogenic drivers and led clinical development plans for several innovative drugs [2] - He has a notable background in precision oncology, having contributed to the approval of Vitrakvi® and Rozlytrek® through his research on NTRK gene fusions [2] Strategic Focus - The company aims to deliver novel treatment options for patients with oncogene amplified cancers, addressing a significant unmet medical need in the oncology space [3][4]

Market Overview - Wall Street experienced volatility at the start of 2025, following a significant sell-off in late 2024, with the Russell 2000 Index dropping 8.4% in December, its worst month since September 2022, but rebounding 0.4% in the first week of 2025 [1] - The "January Effect" is anticipated to drive smoother trading, characterized by a seasonal increase in stock prices during January [1][3] Investment Opportunities - Small-cap stocks that have declined in double digits or high single digits over the past month, with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and a Momentum Score of B or higher, are considered solid investment choices [2] - Notable stocks include: - Boundless Bio Inc. (BOLD): Market cap of $58.4 million, down 15.5% in a month, Zacks Rank 2, Momentum Score A [8] - HomeStreet Inc. (HMST): Market cap of $191 million, down 12% in a month, Zacks Rank 2, Momentum Score A [9] - Synchronoss Technologies (SNCR): Market cap of $96.5 million, down 11% in a month, Zacks Rank 2, Momentum Score A, with an estimated earnings growth rate of 99.3% [10] - Pitney Bowes (PBI): Market cap of $1.3 billion, down 8.4% in a month, Zacks Rank 1, Momentum Score A, with an estimated earnings growth rate of 184.2% [11] - USANA Health Sciences Inc. (USNA): Market cap of $673.2 million, down 8.3% in a month, Zacks Rank 1, Momentum Score A, with an estimated growth of 26.1% [12] Economic Context - The economy is reported to be on solid footing, with household net worth at an all-time high and a healthy labor market, indicating a strong economic outlook [5] - Small-cap companies, being more domestically focused, are expected to outperform as the economy improves, supported by President-elect Trump's policies aimed at deregulation and lower corporate tax rates [5][6] - Reduced regulations are anticipated to lower operational costs for small-cap businesses, enhancing profitability [6] - The Federal Reserve's interest rate cuts, totaling 100 basis points since September, are expected to reduce borrowing costs for small businesses, facilitating expansion and profitability [7]

Core Concept - The "Classic or Nothing" campaign by Tanqueray celebrates its legacy and promotes a return to timeless classics, emphasizing quality over trends [1][3]. Group 1: Campaign Overview - The campaign introduces a vibrant look while maintaining the brand's heritage, featuring striking visuals and a refreshed color palette [2]. - It aims to connect with both existing gin lovers and new cocktail enthusiasts through various marketing activations, including digital media and engaging events [2]. Group 2: Experiential Marketing - The campaign launched with the "Classic or Nothing Diner" at the Austin Food & Wine Festival, merging the classic American diner experience with Tanqueray cocktails [3]. - A subsequent event at MetLife Stadium featured a unique pairing of Tanqueray cocktails with a twist on classic dishes, enhancing guest engagement [4]. Group 3: Brand Heritage - Tanqueray has a rich history of over 180 years, founded by Charles Tanqueray in 1830, and is known for its commitment to quality and innovation [7][8]. - The brand has received numerous awards, including being named 'Bartenders' Choice' in the Drinks International Brand Report 2023, highlighting its esteemed position in the industry [8].

Core Insights - Boundless Bio has decided not to advance BBI-825 into the Part 2 portion of the STARMAP clinical trial due to preliminary pharmacokinetic data and increasing development costs in the competitive landscape of BRAF and KRAS-mutated cancer treatment [2][5][6] - The company is focusing resources on BBI-355, which is on track for initial clinical proof-of-concept data in the second half of 2025, and a third ecDTx program, with a development candidate nomination expected by mid-2025 [3][5][6] - Leadership changes include the departure of Klaus Wagner, M.D., Ph.D., and Neil Abdollahian, with James L. Freddo, M.D., stepping in as Interim Chief Medical Officer [4][6] Pipeline Updates - BBI-355 is currently in a Phase 1/2 POTENTIATE clinical trial, targeting oncogene-amplified solid tumors, with preliminary clinical data expected in the second half of 2025 [3][5] - The decision not to advance BBI-825 was based on a lack of dose-proportional exposure observed in the trial and the complexities of the treatment landscape [3][5] - The third ecDTx program is progressing, targeting a kinesin essential for ecDNA segregation, with an IND application expected in the first half of 2026 [3][5] Leadership Transitions - Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, will leave the company, with James L. Freddo, M.D., taking over as Interim CMO [4][6] - Dr. Freddo has extensive experience in clinical leadership within biopharmaceutical companies [4]

Core Viewpoint - Boundless Bio, Inc. (BOLD) has experienced a significant decline of 19.5% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Indicators - The stock has faced excessive selling pressure, leading to its current oversold status [1]. - The Relative Strength Index (RSI) for BOLD is at 28.72, indicating that the heavy selling may be exhausting itself, which could lead to a price rebound [5]. - A stock is generally considered oversold when its RSI falls below 30, which is a common threshold for identifying potential reversals [2]. Group 2: Earnings Estimates and Analyst Consensus - There is a strong consensus among sell-side analysts that earnings estimates for BOLD have increased by 1.2% over the last 30 days, which typically correlates with price appreciation [6]. - BOLD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers, which affect over 14% of cancer patients [3] - The company is headquartered in San Diego, CA and aims to address significant unmet needs in cancer therapeutics [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapy (ecDTx), BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial for patients with oncogene amplified cancers [3] - The second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial for colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications [3] - The company is also advancing an additional program (ecDTx 3) through preclinical development and discovery using its Spyglass platform [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in Piper Sandler's 36th Annual Healthcare Conference on December 4, 2024, at 3:30 p.m. ET in New York, NY [1][2] - A live and archived webcast of the session will be available on Boundless Bio's website [2]

Financial Performance - The company completed its initial public offering (IPO) in April 2024, selling 6,250,000 shares for gross proceeds of $100.0 million, raising a total of $353.6 million by September 30, 2024[130]. - As of September 30, 2024, the company had cash, cash equivalents, and short-term investments totaling $167.1 million, which is expected to fund operations into the fourth quarter of 2026[130]. - The company recognized incremental non-cash stock-based compensation expense of $857,000 due to option repricing, with $34,000 recognized during the three and nine months ended September 30, 2024[139][140]. - As of September 30, 2024, unrecognized compensation cost related to outstanding time-based options was $20.1 million, expected to be recognized over a weighted-average period of 2.7 years[143]. - The weighted-average grant date fair value of options granted during the three months ended September 30, 2024, was $7.25, compared to $3.23 in the same period of 2023[145]. Research and Development - The company is advancing its third ecDTx program, targeting a kinesin essential for ecDNA segregation, with an Investigational New Drug application (IND) expected in the first half of 2026[127]. - The company has preclinically validated multiple additional ecDNA targets and initiated drug discovery efforts against these targets, retaining global rights for all programs[128]. - The company expects general and administrative (G&A) expenses to increase substantially as it expands headcount to support R&D and potential commercialization activities[136]. Operations and Infrastructure - The company recorded a right-of-use (ROU) asset of $45.8 million and a related lease liability of $45.3 million in November 2024[148]. - The company plans to rely on third parties for the manufacture of its ecDTx, maintaining an efficient infrastructure without investing in its own manufacturing facilities[131].

Financial Performance - Cash position as of September 30, 2024, is $167.1 million, providing an operating runway into the fourth quarter of 2026[6] - Net loss for Q3 2024 totaled $16.5 million, compared to a net loss of $13.2 million in Q3 2023, indicating a 25% increase in losses[6] - Total operating expenses for Q3 2024 were $18.7 million, compared to $15.0 million in Q3 2023, marking an increase of 25.5%[13] - Accumulated deficit as of September 30, 2024, was $185.0 million, compared to $136.1 million at the end of 2023[13] Research and Development - Research and development (R&D) expenses for Q3 2024 were $14.1 million, up from $11.6 million in Q3 2023, representing a 21.5% increase[6] - Initial proof-of-concept data for BBI-355 and BBI-825 clinical trials is expected in the second half of 2025[3][4] - The company is advancing its third ecDTx program, ecDTx 3, through lead optimization[4] General and Administrative Expenses - General and administrative (G&A) expenses for Q3 2024 were $4.6 million, compared to $3.3 million in Q3 2023, reflecting a 39.4% increase[6] Assets and Financial Position - Total assets as of September 30, 2024, were $175.1 million, up from $129.9 million at the end of 2023[13] Clinical Trials and Diagnostics - ECHO, the proprietary diagnostic for detecting ecDNA amplified oncogenes, is currently being used in the BBI-355 POTENTIATE trial[5]

Exhibit 99.1 Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial ongoing with initial proof-of-concept data expected in the second half of 2025 ECHO ecDNA diagnostic analytically validated and IRB-approved for use as a clinica ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share BOLD Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...